PD-1 and PD-L1 Inhibitors Market to Hit USD 89.5 Billion by 2028 with Increase in New Product Launch in Targeted Treatment
Key players includes Merck Co., Bristol-Myers Squibb, Roche, AstraZeneca, Pfizer, Eli Lilly and Company, 4D pharma plc.,Corvus Pharmaceuticals, CytomX Therapeutics, Inc., MacroGenics, Inc., Mirati Therapeutics, Inc., Moderna, Inc., NovoCure Ltd., NeoImmuneTech, Inc., PrimeVax Immuno-Oncology Inc., Incyte Corporation, Trillium Therapeutics Inc.
View full press release